The global market for Lysosomal Storage Diseases was estimated at US$10.4 Billion in 2023 and is projected to reach US$15.2 Billion by 2030, growing at a CAGR of 5.6% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.
Key Insights:
- Market Growth: Understand the significant growth trajectory of the Enzyme Replacement Therapy (ERT) segment, which is expected to reach US$7.3 Billion by 2030 with a CAGR of a 6.1%. The Substrate Reduction Therapy (SRT) segment is also set to grow at 5.3% CAGR for the next 7-year period.
- Regional Analysis: Gain insights into the U.S. market, estimated at $3.2 Billion in 2023, and China, forecasted to grow at an impressive 5.3% CAGR to reach $2.6 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Lysosomal Storage Diseases Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Lysosomal Storage Diseases Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Lysosomal Storage Diseases Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of major players such as Alexion Pharmaceuticals, Inc., BioMarin Pharmaceutical, Inc., Horizon Therapeutics plc, and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Select Competitors (Total 44 Featured):
- Alexion Pharmaceuticals, Inc.
- BioMarin Pharmaceutical, Inc.
- Horizon Therapeutics plc
- Lacerta Therapeutics
- Orphazyme ApS
- Oxyrane
- Sanofi Genzyme
- Sanofi SA
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERSIII. MARKET ANALYSISIV. COMPETITION
1. MARKET OVERVIEW
4. GLOBAL MARKET PERSPECTIVE
UNITED STATES
CANADA
JAPAN
CHINA
EUROPE
FRANCE
GERMANY
ITALY
UNITED KINGDOM
REST OF EUROPE
ASIA-PACIFIC
REST OF WORLD
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Alexion Pharmaceuticals, Inc.
- BioMarin Pharmaceutical, Inc.
- Horizon Therapeutics plc
- Lacerta Therapeutics
- Orphazyme ApS
- Oxyrane
- Sanofi Genzyme
- Sanofi SA
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 193 |
| Published | March 2025 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value ( USD | $ 10.4 Billion |
| Forecasted Market Value ( USD | $ 15.2 Billion |
| Compound Annual Growth Rate | 5.6% |
| Regions Covered | Global |
